← HomeGLOBAL OBESITY TRACKERby OneAlphaMed
Updated 21 Oct, 9:02 pm IST· 4× daily · 8am 12pm 4pm 8pm
GLOBAL OBESITY TRACKER · ANTI-OBESITY / GLP-1 · COMPETITIVE INTELLIGENCE

Global obesity tracker

Live competitive-intelligence for the global anti-obesity / GLP-1 market

Market sizing, launches, pipeline, efficacy and news across 13 markets. Every claim linked to a primary source. Showing: Global — worldwide totals plus each market in US$; per-market figures are not summed.

GLOBAL ANTI-OBESITY MARKET CONTEXT
US$66bn
+39% YoY
FORECAST · GLOBAL OBESITY-MEDICINES
US$92bn
+39% vs 2025 (US$66bn→US$92bn)
GLOBAL OBESITY MEDICINES MARKET, 2
US$105–200bn
n/a (range as given by source)
REGION
PORTFOLIO OPPORTUNITY SCREEN · MANDATE: INDIAN GENERICS MANUFACTURER

Which markets clear the gates — and what is still unknown

Post-patent semaglutide / liraglutide generics, cost-led; India plus emerging-market export. Gates are decided before any attractiveness comparison, and a failed gate is not offset by a good number elsewhere. Unknown is not a soft pass — it is shown hollow and becomes a named diligence task.

NEAR-TERM COMMERCIAL9 MARKETS

A generic of the target molecules is already lawfully marketed here, so entry has been demonstrated by others.

IP / LAWFUL ENTRYREGULATORY ROUTEOBESITY INDICATIONACCESS ROUTECMC / SUPPLYPERFORMANCE MATRIX — NOT AGGREGATED
STRATEGIC PIPELINE4 MARKETS

No marketed target-molecule generic found. Entry depends on filing ahead of, or resolving, the local exclusivity position.

IP / LAWFUL ENTRYREGULATORY ROUTEOBESITY INDICATIONACCESS ROUTECMC / SUPPLYPERFORMANCE MATRIX — NOT AGGREGATED
Diligence triage from tracked market evidence — not legal, regulatory, FTO or investment advice. Gate verdicts require sign-off from regulatory, IP counsel, quality and supply owners before any commitment.
COMPARE MARKETS · ALL REGIONS

Market attractiveness — 13 markets compared

HIGHEST FIRST

Obesity-indication market value (US$m)

Revenue available today. Large means proven willingness to pay; small can mean early, or blocked.

⚠ Scope differs by market — some figures are obesity-indication only, others the whole weight-management category. Open a bar to see the basis and source.

NOT PUBLISHED — 3 MARKETS EXCLUDED FROM THIS RANKING

Indonesia · European Union · United States — no Tier-1 or primary source publishes this metric for these markets. They are shown here rather than plotted at zero, which would rank them last on a figure nobody has measured.

Figures are not summed and not re-based — each is the market's own published number on its own basis and date. Expand any bar for the basis and the source.
◆ OneAlphaMedEach market shown in its own currency; US$ conversions use the FX basis stated in that market’s briefFor professional use only · Not investment adviceMarket-size figures are point-in-time estimates from research firms whose methodologies differ — treat as directionalonealphamed.comLinkedInEmbed